期刊文献+

无创性动态血压监测评价复方坎地沙坦酯片治疗原发性高血压患者的疗效 被引量:1

Antihypertensive Efficacy of Compound Candesartan Cilexetil/HTCZ Assessed by 24-hour Ambulatory Blood Pressure Monitoring in Patients With Essential Hypertension
下载PDF
导出
摘要 目的:用无创性动态血压监测仪评价国产复方坎地沙坦酯片(坎地沙坦酯16 mg/氢氯噻嗪12.5 mg)对原发性高血压患者的降压疗效。方法:原发性高血压患者经过2周清洗期后,进入坎地沙坦酯片8 mg 单药治疗期,对4周后坐位血压未达标者(达标为血压<140/90 mmHg),进行24小时动态血压监测,以随机双盲、平行对照试验方法,分别服用复方坎地沙坦酯片(复方坎地沙坦酯组,28例)或16 mg 坎地沙坦酯片(坎地沙坦酯组,27例)治疗8周。比较两组服药前后24小时动态血压参数变化。观察组内与组间服药前后的不同时段的血压变化,谷峰比值及血压平滑指数。结果:共55例患者完成动态血压监测,两组基础指标比较无差异。复方坎地沙坦酯组与坎地沙坦酯组药后收缩压/舒张压/平均动脉压全日平均值(24小时)、日间平均值(6:00~22:00)、夜间平均值(22:00~6:00)均明显下降,与同组基线值比较均有极显著性差异(P<0.01)。组间比较,复方坎地沙坦酯组收缩压/舒张压/平均动脉压全日平均值(24小时)、日间平均值(6:00~22:00)、夜间平均值(22:00~6:00)的降低幅度与坎地沙坦酯组比较均有极显著性差异(P<0.01)。服药谷峰比值(SBP/DBP)复方坎地沙坦酯组分别为99.36%(19.16/19.28 mmHg)和87.36%(10.14/11.61 mmHg),复方坎地沙坦酯组分别为54.42%(7.30/13.41 mmHg)和64.86%(6.43/9.91 mmHg)。血压平滑指数(SBP/DBP)在复方坎地沙坦酯组为4.53/3.91,坎地沙坦酯组为1.29/1.52。结论:复方坎地沙坦酯片对原发性高血压患者有较好的降压作用,复方制剂比单药降压幅度大、持续时间长。动态血压平均下降幅度日间>全天>夜间,收缩压>舒张压。复方坎地沙坦酯控制血压更平稳。 Objectives : To compare the antihypertensive efficacies of candesartan cilexetil 16 mg/HTCZ12. 5 mg with candesartan cilexetil 16mg after 8 weeks treatment by 2d-hour ambulatory blood pressure monitoring(ABPM). Methods: A randomized, double-blind, parallel-group study of Can/HTCZ (group 1 ) versus Can (group 2) was conducted in 55 patients with mild-to-moderate essential hypertension whose target sitting diastolic BP was not achieved ( SeDBP 〈 90 mmHg)after 4 weeks treatment with 8 mg candesartan cilexetil once-daily were undergone ABPM. Changes of daytime and night-time diastolic (DBP) and systolic blood pressures (SBP) by ABPM were compared. Tough peak ratio (TPR)and smoothness index (SI) were calculated for each group. Results: The mean BP(SBP/DBP) at 24h,daytime and night-time by ABPM in group 1 (n = 28 ) decreased by 15.86 ± 8. 24/8.75 ± 6. 23 mmHg, 17.04 ± 9. 60/10.00 ± 6. 87 mmHg and 14.61 ± 9.92/7.64 ± 7. 57 mmHg ; and in group 2 ( n = 27 ) decreased by 5.15 ± 7.67/4. 44 ± 4.59 mmHg,6. 70 ± 7. 12/5.26 ± 4.49 mmHg and 4. 11 ± 10.78/3.52 ± 6. 47 mmHg respeetively. The T/P ratio of SBP and DBP were 99.36% ( 19. 16/19. 28 mmHg) and 87.36% ( 10. 14/11.61 mmHg)in group 1 ; and 4.42% (7.30/ 13.41 mmHg) and 64. 86% (6.43/9.91 mmHg)in group 2 respectively. Conclusion:Compared with Can 16 mg,the compound Can 16 mg and HCTZ 12. 5 mg presented the better effect to the pa- tients with essential hypertension, and the compound product could reduce the blood pressure in a greater degree with longer time. The everage ambulatory blood pressure reducing model was like day time 〉 whole day 〉 night time, SBP 〉 DBP. The compound product may decease the blood pressure in a smoother way.
出处 《中国循环杂志》 CSCD 北大核心 2007年第6期447-450,共4页 Chinese Circulation Journal
关键词 原发性高血压 复方坎地沙坦酯片 动态血压监测 谷峰比值 平滑指数 Essential hypertension Compound candesartan cilexetil Ambulatory blood pressure monitoring T/P ratio Smoothness index
  • 相关文献

参考文献6

二级参考文献28

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2JNC 7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. U. S. National Institute of Health- National Heart, Lung, and Blood Institute,NIH Publication No. 03 - 5233, May 2003.
  • 3Claude Lenfant, Aram V. Chobanian, Danicl W. Jones, et al. Resetting the hypertension sails[J]. Hypertension, 2003,41:1178-1179.
  • 4Janice Hopkins Tanne. US guidelines say blood pressure of 120/80 mmHg is not "normal"[J].BMJ. 2003,326:1104.
  • 5Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
  • 6Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
  • 7Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
  • 8中国高血压防治指南起草委员会.1999中国高血压防治指南[J].高血压杂志,2000,8:94-112.
  • 9European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
  • 10Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.

共引文献2936

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部